ArTS Archivio della ricerca di Trieste

MACOR, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.460
EU - Europa 3.623
AS - Asia 841
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 9
OC - Oceania 7
Totale 9.981
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.270
PL - Polonia 1.528
IT - Italia 552
SE - Svezia 486
CN - Cina 291
DE - Germania 271
UA - Ucraina 245
CA - Canada 190
SG - Singapore 176
HK - Hong Kong 169
GB - Regno Unito 117
FI - Finlandia 104
TR - Turchia 93
BG - Bulgaria 83
IE - Irlanda 70
BE - Belgio 43
FR - Francia 39
VN - Vietnam 38
SN - Senegal 27
RU - Federazione Russa 21
IN - India 19
KR - Corea 17
CZ - Repubblica Ceca 14
CH - Svizzera 11
ES - Italia 10
JP - Giappone 9
NL - Olanda 9
IR - Iran 8
EU - Europa 7
AU - Australia 6
RO - Romania 4
TW - Taiwan 4
GR - Grecia 3
PT - Portogallo 3
SA - Arabia Saudita 3
TN - Tunisia 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
AR - Argentina 2
BD - Bangladesh 2
CO - Colombia 2
EG - Egitto 2
HU - Ungheria 2
MO - Macao, regione amministrativa speciale della Cina 2
MY - Malesia 2
PK - Pakistan 2
UY - Uruguay 2
AL - Albania 1
AT - Austria 1
BR - Brasile 1
EC - Ecuador 1
EE - Estonia 1
HR - Croazia 1
ID - Indonesia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PE - Perù 1
RS - Serbia 1
Totale 9.981
Salva come PNG Salva come JPEG
Città #
Warsaw 1.528
Woodbridge 644
Fairfield 616
Chandler 547
Ann Arbor 517
Ashburn 395
Houston 353
Wilmington 310
Jacksonville 253
Trieste 253
Seattle 232
Cambridge 192
Hong Kong 168
Munich 165
Montréal 151
Mcallen 143
Princeton 140
Singapore 126
Izmir 88
Sofia 82
Beijing 81
Dublin 70
Dearborn 46
San Diego 40
Brussels 38
Redmond 38
Dong Ket 37
Helsinki 36
Falls Church 31
Toronto 28
Dakar 27
Boardman 26
Redwood City 25
Milan 24
Des Moines 20
Sacile 19
Santa Clara 18
Washington 16
Düsseldorf 14
Hefei 14
Shanghai 14
Brno 13
Jinan 13
Seoul 13
Buffalo 12
Phoenix 12
Nanjing 11
Rome 11
Bern 10
Chicago 10
Norwalk 10
Udine 8
Kunming 7
Los Angeles 7
Bremen 6
Cascina 6
Centro 6
Detroit 6
Fremont 6
Guangzhou 6
Padova 6
San Mateo 6
Dongguan 5
Fuzhou 5
Hebei 5
Palermo 5
Paris 5
Sint-Genesius-Rode 5
Amsterdam 4
Chennai 4
Columbus 4
Latina 4
Monfalcone 4
Pradamano 4
Taizhou 4
Tianjin 4
Tokyo 4
Trivandrum 4
Verona 4
Zhengzhou 4
Azzano Decimo 3
Barcelona 3
Clearwater 3
Dallas 3
Hangzhou 3
Indiana 3
Kaohsiung 3
Leawood 3
Madeirã 3
Montreal 3
Nanchang 3
North Bergen 3
Pisa 3
Saint Louis 3
San Francisco 3
Shenyang 3
Thuwal 3
Venezia 3
Vicenza 3
Wuhan 3
Totale 7.888
Salva come PNG Salva come JPEG
Nome #
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications 718
Meniscal ossicles as micro-CT imaging biomarker in a rodent model of antigen-induced arthritis: A synchrotron-based x-ray pilot study 351
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies 345
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 313
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers 312
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage 308
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: Evidence for the importance of an early diagnosis 286
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 253
New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats 239
A non-complement-fixing antibody to  2 glycoprotein I as a novel therapy for antiphospholipid syndrome 229
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. 227
Complement as a biological tool to control tumor growth 208
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. 203
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. 202
Targeted nanoparticles and complement activation 185
null 166
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles 162
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 161
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. 160
The seventh complement component is expressed on endothelial cells membrane and exerts an anti-inflammatory action 156
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. 155
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating 153
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 151
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy 147
Complement as effector system in cancer immunotherapy. 143
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5 142
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia 129
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. 128
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. 127
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. 126
A Human Monoclonal Antibody Against Domain I Of beta 2-Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models. 124
Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. 118
Alterations in trabecular bone μ-architecture and cartilages in rats with antigen-induced arthritis (AIA) resulting from synchrotron-based X-ray imaging analysis 118
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. 117
null 117
Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. 115
Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. 112
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 112
Complement in human diseases: Lessons from complement deficiencies. 110
Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. 110
null 105
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells 104
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study 104
Humoral immunotherapy of multiple myeloma: perspectives and perplexities. 103
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. 102
DEVELOPMENT OF CHLORAMBUCIL/HYDROXYCHLOROQUINE-LOADED ANTI-CD20 NANOPARTICLES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA : IN VITRO MODEL 102
The development of atypical hemolytic uremic syndrome depends on complement C5. 99
Simple scale-up of recombinant antibody production using an UCOE containing vector 98
Cubosomes for in vivo fluorescence lifetime imaging 96
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis 95
OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis 93
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies 92
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis 90
P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. 88
Effects of chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles on a human/mouse model of Burkitt lymphoma 82
FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis 78
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target 72
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination 71
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I 68
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab 65
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids 64
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model 64
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition 56
Constitutive psgl-1 correlates with cd30 and tcr pathways and represents a potential target for immunotherapy in anaplastic large t-cell lymphoma 56
Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity 55
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients 55
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties 54
Phage Display Technology for Human Monoclonal AntibodiesHuman Monoclonal Antibodies 51
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 46
Complement system and phagocytosis in a colonial protochordate 46
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. 45
The J-elongated conformation of b2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome 44
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. 42
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies 29
Plasminogen activator-coated nanobubbles targeting cell-bound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy 29
Hereditary deficiency of the second component of complement: Early diagnosis and 21-year follow-up of a family 22
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma 19
Totale 10.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.796 0 0 0 350 190 264 232 205 193 141 142 79
2020/20211.380 183 100 112 146 118 119 92 105 82 120 66 137
2021/20221.020 97 75 74 88 21 69 38 36 128 99 55 240
2022/20231.493 131 232 120 238 90 254 30 147 175 16 45 15
2023/2024886 55 49 52 37 109 123 135 167 16 28 78 37
2024/2025235 23 72 113 27 0 0 0 0 0 0 0 0
Totale 10.322